21 March 2023
SHARE NOW
Cell Therapy
Gene Editing
Patient Access & Engagement
Justin McCue, CTO at Avectas, describes the mechanism and benefits of Solupore as well as the impact the technology will have on patient populations.
Justin explains how the rapid but gentle process of Solupore ensures a healthy and highly functioning cell, before comparing the outcomes with other industry processes.
Justin then considers the overall impact these outcomes can have to the patient, including a streamlined process end-to-end, as well as smaller, highly efficacious dosing.
This interview has been produced in partnership with Avectas and was recorded at Advanced Therapies Week 2023.
 |
 |
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
8 June 2023
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
UK-based independent innovation and technology organization Cell and Gene Therapy Catapult (CGT Catapult), has officially opened new laboratories and offices in Edinburgh, Scotland, UK, BioQuarter – enhancing Edinburgh’s role as a hub for cell therapies.
7 June 2023
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
5 June 2023
Discover more like this
